Vir Biotechnology (VIR) EPS (Weighted Average and Diluted) (2020 - 2026)
Vir Biotechnology's (VIR) quarterly EPS (Weighted Average and Diluted) came in at -$0.85 in Q1 2026, up 3.41% year-on-year from -$0.82 in Q1 2025, and down 183.33% quarter-over-quarter from -$0.3 in Q4 2025.
Vir Biotechnology (VIR) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Vir Biotechnology has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$0.85 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.85, up 3.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.12 (up 26.07% YoY), and the FY2025 annual result was -$3.16, up 17.49% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.85 for Q1 2026 at Vir Biotechnology, down from -$0.3 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.85 in Q1 2022 to a low of -$1.56 in Q3 2024.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.85 (2026), against an average of -$0.51.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 391.67% in 2022, while the deepest fall reached 226.09% in 2022.
- Vir Biotechnology's EPS (Weighted Average and Diluted) stood at -$0.75 in 2022, then fell by 14.67% to -$0.86 in 2023, then advanced by 11.63% to -$0.76 in 2024, then surged by 60.53% to -$0.3 in 2025, then plunged by 183.33% to -$0.85 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.85 (Q1 2026), -$0.3 (Q4 2025), and -$1.17 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Vir Biotechnology | 1.35 Bn | 1.35 Bn | - | -0.85 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.85 |
| Dec 31, 2025 | -0.30 |
| Sep 30, 2025 | -1.17 |
| Jun 30, 2025 | -0.80 |
| Mar 31, 2025 | -0.88 |
| Dec 31, 2024 | -0.76 |
| Sep 30, 2024 | -1.56 |
| Jun 30, 2024 | -1.02 |
| Mar 31, 2024 | -0.48 |
| Dec 31, 2023 | -0.86 |
| Sep 30, 2023 | -1.22 |
| Jun 30, 2023 | -1.45 |
| Mar 31, 2023 | -1.06 |
| Dec 31, 2022 | -0.75 |
| Sep 30, 2022 | 1.30 |
| Jun 30, 2022 | -0.58 |
| Mar 31, 2022 | 3.85 |
| Dec 31, 2021 | 3.94 |
| Sep 30, 2021 | 0.82 |
| Jun 30, 2021 | 0.46 |